Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Academic Article 2017 uri icon


  • Margolis DA
  • Gonzalez-Garcia J Stellbrink HJ Eron JJ Yazdanpanah Y Podzamczer D Lutz T Angel JB Richmond G
  • Clotet B
  • Sloan L Clair MS Murray M Ford SL Mrus J Patel P Crauwels H Griffith SK Sutton KC Dorey D
  • Smith KY Williams PE Spreen WR

publication date

  • 2017

published in